Regenxbio

US · RGNX #3748 by market cap Listed 2015

7.60 +0.15 +1.95%

Live - 5344 symbols - heartbeat 215s ago · 2026-10-08 07:07

Pre-market 7.50 -1.25%

After-hours 7.61 +0.21%

Overnight 7.86 +3.49%

Market cap: 501.37M
P/E (TTM): -2.01
P/B: 6.99
EPS: -3.76
Div yield: 0.00%
52W pos: 20%

Reader sentiment Are you bullish or bearish on RGNX?

Anonymous reader poll. Unscientific, not investment advice.

About Regenxbio

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Founded: 2008
CEO: Mr. Curran Simpson
Employees: 371
Headquarters: Rockville, Maryland, United States of America
Fiscal year end: 12-31
Website: regenxbio.com

Company profile

Exchange: US
Symbol: RGNX
Market-cap rank: #3748
Listing date: 2015-09-17
Market cap: 501.37M
Float cap: 434.67M
Shares out: 66.01M
Float shares: 57.23M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 07:07:57 · For reference only, not investment advice and not tailored to your situation.